AstraZeneca and Daiichi Sankyo are challenging Gilead Sciences for dominance in one of the toughest-to-treat breast cancers in a race for patients — and profits.
Irritable bowel syndrome (IBS) is a common disorder that causes bloating, diarrhea, cramping and abdominal pain.
In the realm of gastroenterology, inflammatory bowel disease (IBD), encompassing Crohn’s disease (CD) and ulcerative colitis (UC), presents a significant therapeutic challenge due to its chronic ...
Latest analysis of U.S. real-world evidence demonstrates improved clinical outcomes when cefiderocol is used as earlier ...
Trodelvy plus Keytruda may maintain QOL and delay physical decline in PD-L1-positive mTNBC patients. The combination therapy showed improved progression-free survival and reduced symptom burden ...
Long-term continuous OGSIVEO treatment for up to 4 years was associated with further tumor size reductions, increase in objective response rate, sustained improvement in desmoid tumor symptoms and con ...
UNEP, WHO data reveal massive destruction of Gaza’s ecosystem, collapse of water, food, and agriculture systems due to ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果